All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-06-19T08:54:17.000Z

EHA 2019 | GOYA trial: Prognostic value of metabolic tumor volume in DLBCL

By Emily Smith, Marek Trněný
Featured
Marek Trněný
Jun 19, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Marek Trněný from the Charles University General Hospital, Prague, CZ, talks about GOYA trial and the prognostic value of metabolic tumor volume in diffuse large B-cell lymphoma (DLBCL).

Marek Trněný highlights one of the main questions in the field; how do we manage patients failing therapy and how can we define refractory patients? Whilst the GOYA study was negative, one thing the group evaluated was how to identify refractory patients or those at risk of early relapse (within 12 months).
 
One method to do this was to measure total metabolic tumor volume. The group found that patients in 4th quartile had a higher chance of developing refractory disease and so defined a cut-off to predict this. It was concluded that if this cut-off is applied to daily practice, it may be possible to start subsequent treatment earlier or use more intensive treatment in these patients.

GOYA trial: Prognostic value of metabolic tumor volume in DLBCL

More about...
Aggressive B-cell lymphomasDiffuse large B-cell lymphomaEHA 2019GOYAObinutuzumabRituximab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 49 days left ...

Related articles

Add bookmark

Combination of COO and CNS-IPI improves CNS relapse prognosis in DLBCL

The aim of this analysis was to investigate the impact of cell-of-origin (COO), CNS-IPI, and BCL2/MYC double-expression on CNS relapse in the DLBCL patients from the phase III...

Jan 31, 2019
Add bookmark

Combination of COO and CNS-IPI improves CNS relapse prognosis in DLBCL

The aim of this analysis was to investigate the impact of cell-of-origin (COO), CNS-IPI, and BCL2/MYC double-expression on CNS...

Jan 31, 2019
Add bookmark

Prof. Marek Trneny | EBMT 2018 | What were the most interesting results from EBMT?

What were the most interesting results from EBMT?

Mar 23, 2018
Add bookmark

Prof. Marek Trneny | EBMT 2018 | What were the most interesting results from EBMT?

What were the most interesting results from EBMT?

Mar 23, 2018

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox